Gluva Health is developing a platform designed to connect CGM wellness outcomes to employer health plan claims data — with the goal of giving self-funded employers meaningful evidence that their wellness investment is working.
Gluva Health will analyze your TPA claims extract and PBM drug utilization data to identify employees with pre-diabetic indicators, metabolic pharmacy spend, and GLP-1 exposure — before they cost your plan more. Risk identification is driven entirely by actual claims data, not voluntary screening or health fairs.
High-risk employees will receive a continuous glucose monitor and personalized dietitian sessions anchored to their actual glucose data — not generic nutrition advice. Interventions will concentrate on the employees with the highest room for measurable improvement, making every dollar of program spend count.
After one plan year, Gluva Health will pull an updated claims extract and compare participant glucose improvements against plan cost trends — looking for measurable reductions in metabolic claims spend that may support more favorable stop-loss underwriting and lower long-term health plan cost projections.
The Gluva Health employer dashboard is currently in active development. The preview below illustrates the reporting capabilities being built for employer partners — showing the type of claims-linked ROI documentation that becomes available once the platform is fully integrated with your TPA.
Gluva Health's financial methodology is anchored to published clinical and economic studies. Every savings assumption traces to a named peer-reviewed study and a documented methodology.
Kuo et al. — N=5,948 employees with prediabetes in employer-sponsored health plans. $4,552 in direct medical savings per enrollee over 2 years. 88% probability program was cost-saving. 2.8 percentage-point absolute diabetes risk reduction.
Aetna retrospective analysis — N=7,336 patients with diabetes. CGM initiation associated with −31% all-cause hospitalizations, −67% diabetes-related admissions, and −40% diabetes-related ED visits. All findings p<0.0001.
Parker et al. — Average annual cost per diagnosed diabetes patient: $22,540 in direct medical and pharmacy costs. People with diabetes have medical expenditures 2.6× higher than those without. GLP-1 therapy adds $18,000–$30,000+ per member per year at commercial plan rates.
2,000 to 30,000 covered lives. You bear 100% of your plan's claims cost. Gluva Health will give your CFO the documented ROI framework that justifies the wellness budget and supports cost trajectory reduction — once fully integrated with your TPA.
Differentiate your practice with a wellness program designed to produce claims-linked ROI documentation at every renewal. Early broker partners will have input on platform features and preferred client onboarding.
Gluva Health's claims-linked outcomes methodology is designed to provide underwriters with meaningful data on risk reduction in the employer's highest-cost cohort — supporting more informed renewal conversations.
Gluva Health's standard claims extract format is designed to work with any TPA. One data authorization from the employer plan sponsor produces the baseline needed to identify high-risk employees and document program outcomes.
Gluva Health is currently accepting expressions of interest from self-funded employers, brokers, and TPA partners ahead of our official launch. Early partners will have direct input on platform development and preferred onboarding access.
Express Interest